Depression Screening & Care
This module will help practices apply the medical home attributes to the care of patients with depression.
Why is this important?
The estimated lifetime prevalence of depression is 13.2%. Depressive episodes can occur from adolescence through old age, but the median age of onset is 32. Depressive disorders are very common in primary care settings, with a prevalence of 26% of patients with any mood disorder, and 12% with major depressive disorder. Depression is a chronic condition which requires long-term management. Practices need to be prepared and proactive in order to deliver excellent depression care.
How will these tools help?
This module introduces methods of screening for depression and tools and resources to help most primary care practices implement a team-based, collaborative approach to helping people with depression.
This module is intended to be used by the following practice staff:
- Physician Assistants
- Nurse Practitioners
- Registered Nurses
- Medical Assistants
- Practice Managers
ACP Clinical Practice Guideline: Using Second-Generation Antidepressants to Treat Depressive Disorders
Faculty list and disclosure information
- Meghan Gannon, MSPH2 - Clinical Programs Administrator, American College of Physicians, Philadelphia, PA
- Steven Hahn, MD2 - Professor of Clinical Medicine Instructor in Psychiatry, Albert Einstein College of Medicine
- Wayne Katon, MD2 - Professor, Vice-Chair, Director of Division of Health Services and Psychiatric Epidemiology, Washington Medical School
- Theresa Kanya, MBA1 - Vice President, Medical Education and Publishing Division, American College of Physicians, Philadelphia, PA
- Amir Qaseem, MD, PhD, MHA2 - Director of Clinical Policy, American College of Physicians, Philadelphia, PA
- Melissa Starkey, PhD1 - Clinical Guidelines Administrator, American College of Physicians, Philadelphia, PA
- Has no financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
- Has disclosed financial relationship(s) with an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
The following committee members have disclosed significant relationships with relevant commercial companies or organizations:
- Meghan Gannon, MSPH - Research Grants/Contracts: Astra Zeneca, Bristol Meyers Squib
- Steven Hahn, MD - Lecture: Pfizer Opthalmics, Canada; Kissito Healthcare
- Wayne Katon, MD - Lecture Honorium: Lily, Forrest Pharmaceuticals, Pfizer, Wyeth; Research Grants/Contracts: NIMH
- Amir Qaseem, MD, PhD, MHA - Research Grants/Contracts: Astra Zeneca, Bristol Meyers Squib
The content of this module is based on an American College of Physicians Clinical Practice Guideline written by: Meghan Gannon, MSPH; Steven Hahn, MD; Wayne Katon, MD; Theresa Kanya, MBA; Amir Qaseem, MD, PhD, MHA; Melissa Starkey, PhD.
This module was made possible by funding from AstraZeneca and Bristol-Myers Squibb.
- 1.00 Attendance
- 20.00 ABIM MOC